US 12,253,460 B2
Drug detection using cobalt thiocyanate and Eosin Y
Jeremy Canfield, Bowling Green, OH (US); Jon Sprague, Bowling Green, OH (US); Sandip Agarwal, Woburn, MA (US); Kateland Herault, Woburn, MA (US); and Mark Benjamin Volkin, Walpole, MA (US)
Assigned to Bowling Green State University, Bowling Green, OH (US); and Vuronyx Technologies LLC, Woburn, MA (US)
Appl. No. 17/910,926
Filed by Bowling Green State University, Bowling Green, OH (US); and Vuronyx Technologies LLC, Woburn, MA (US)
PCT Filed Mar. 11, 2021, PCT No. PCT/US2021/021824
§ 371(c)(1), (2) Date Sep. 12, 2022,
PCT Pub. No. WO2021/183719, PCT Pub. Date Sep. 16, 2021.
Claims priority of provisional application 63/049,805, filed on Jul. 9, 2020.
Claims priority of provisional application 62/988,676, filed on Mar. 12, 2020.
Prior Publication US 2023/0137342 A1, May 4, 2023
Int. Cl. B01L 3/00 (2006.01); B01F 33/302 (2022.01); B01F 33/3033 (2022.01); B01L 7/00 (2006.01); C12Q 1/6848 (2018.01); C12Q 1/686 (2018.01); G01N 21/29 (2006.01)
CPC G01N 21/29 (2013.01) 14 Claims
OG exemplary drawing
 
1. A testing assay comprising a substrate having a first area with Eosin Y thereon and a second area having cobalt thiocyanate thereon;
wherein the first area comprises Eosin Y aggregates created with from 0.005% w/w to 0.2% w/w Eosin Y and from 0.005% w/w to 0.5% w/w phosphotungstic acid in a citrate or phosphate buffer.